Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.995 USD | -3.62% | -8.03% | -39.79% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-39.79% | 235M | C- | ||
-3.00% | 102B | B+ | ||
+1.97% | 96.29B | B+ | ||
+2.13% | 22.18B | B | ||
-15.40% | 21.2B | B+ | ||
-9.21% | 18.31B | A- | ||
-39.98% | 17.38B | A- | ||
-15.45% | 16.36B | B | ||
+4.88% | 13.97B | C+ | ||
+32.45% | 12.17B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CHRS Stock
- Ratings Coherus BioSciences, Inc.